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Revising messages traveling along the cellular 
information superhighway 
Cells use RNA messages to carry instructions from the genome to ribosomes about 
the types of proteins that should be made. These messages are generally revised 
by splicing before translation. Engineering ribozymes that can use splicing 
to repair mutant transcripts may be a useful approach to gene 
therapy of several genetic diseases. 
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DNA genomes house instructions for building a vast 
array of biological molecules that are required to main- 
tain life. This organization dictates that the conversion of 
these genetic instructions into needed macromolecules 
is a seminal event in cellular morphogenesis and metab- 
olism. The molecular mechanism underlying this trans- 
formation has been extensively studied for the past 
several decades. Here, I will briefly review the role of 
RNA in this information conversion and speculate on 
how we may be able to employ RNA to rewrite genetic 
instructions for therapeutic ends. 
The RNA stretch of the cellular information superhighway 
RNA molecules have been found to be key participants 
at several stages in the pathway used by eukaryotic cells to 
convert the warehouse of information stored in DNA 
genomes into needed biomolecules (Fig. 1). As every first- 
year biology student knows, the information contained in 
a given protein-encoding gene is directly copied into the 
corresponding pre-messenger RNA by transcription.The 
information embedded in this RNA is not fixed, 
however, and can be modified by splicing [l-4] or editing 
[5-71 to remove, add, or rewrite parts of the initial tran- 
script. Interestingly, many of the molecules involved in 
revising the RNA messages are RNAs themselves. Small 
RNAs found in abundant ribonucleoprotein (RNP) par- 
ticles are involved in pre-mRNA processing [1,8], and 
guide RNAs are thought to direct RNA editing in 
kinetoplastids [5,9]. Once revisions are complete, the 
rewritten messages are translated to produce the proteins 
Fig. 1. The cellular information super- 
highway. DNA is transcribed into 
pre-messenger RNA (pre-mRNA) then 
revised by splicing, mediated by small 
nuclear RNAs (snRNAs) or self-splicing 
reactions, to give messenger RNA 
(mRNA). The mRNA is transported out 
of the nucleus before translation, 
which requires ribosomal RNAs 
(rRNAs) and transfer RNAs (tRNAs). 
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that are needed at that moment.Two additional types of 
RNA molecules, ribosomal RNAs and transfer RNAs, 
are required for this decoding step [lo]. 
Obviously this RNA-centered overview of cellular 
information flow is greatly oversimplified. Many proteins 
and other cellular factors are required to regulate gene 
expression. However, it serves to make the point that a 
fundamental role of RNA molecules in cells is to help 
manage the use of genetic information. RNA transcripts 
appear to be th e sole carriers of instructions from the 
genome to the ribosome. Such RNA couriers can also 
be thought of as storage molecules; the content of what 
is stored can be easily modified by other RNAs, the mol- 
ecular relatives of the couriers. Most of the modifying 
RNAs collaborate with proteins, forming RNPs. 
Ribozymes as revisionists 
Not all message revisions require proteins. Certain group 
I and group II intron RNAs can excise themselves from 
precursor transcripts without the aid of protein [ll-151. 
In the process, the introns ligate flanking exon sequ- 
ences together and produce a processed RNA with a 
revised primary sequence. These self-splicing reactions 
Fig. 2. Comparison of self-splicing and 
trans.splicing by the Tetrahymena group 
I ribozyme. (a) Self-splicing is initiated 
by attack of the 5’ splice site with an 
intron-bound guanosine. This cleavage 
occurs just 3’ of the uridine (shown in 
red) which is involved in a G-U base 
pair. The intron (green) holds onto the 
cleaved 5’ exon via base pairing 
through its 5’ exon binding sequence 
(green and in lower case: gn’n’n’n’n’). 
Ligation of the freed 5’ exon (dark blue) 
to the 3’ exon (yellow) splice site yields 
a processed RNA. (b) In trans-splicing, 
the ribozyme recognizes the substrate 
RNA by base pairing to the sequence 
(5’-NNNNNU-3’) through the comple- 
mentary 5’ exon-binding site (S’- 
gn’n’n’n’n’-3’) of the ribozyme. The 
ribozyme cleaves the bound substrate at 
the reactive uridine (red), releases the 3’ 
cleavage product (light blue) and holds 
onto the 5’ cleavage product (dark 
blue). Exon ligation then proceeds as in 
the self-splicing reaction. 
are accomplished by catalytic centers composed entirely 
of RNA residues that are formed by complex tertiary 
folding of the intron sequences. Examples of such self- 
splicing RNA enzymes or ribozymes have been found in 
the genomes of a range of eukaryotic organisms, 
although they have not yet been found in vertebrates. 
The self-splicing reaction of the group I intron ribo- 
zyme from Etvukymena tkemopkila is perhaps the most 
thoroughly understood reaction that revises RNA. The 
intron performs two consecutive trans-ester&cation 
reactions to liberate itself and join flanking exons (Fig. 
2a) [15,16]. In the first reaction, an intron-bound 
guanosine attacks the phosphodiester bond at the 5’ 
splice site that is defined by a conserved, unconven- 
tional G-U base pair [17]. In the second reaction, the 
free 3’ hydroxyl group, now present on the end of the 
cleaved 5’ exon, attacks the phosphorus atom at the 3’ 
splice site to result in the liberation of the intron and 
the ligation of the 5’ and 3’ exons. Careful character- 
ization of this reaction over the past decade has illus- 
trated that the vast majority of sequence requirements 
for this self-splicing are contained within the intron. 
No specific sequence requirements exist for the 3’ exon 
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[16], and the only specific sequence requirement for 5’ 
exons is to have a uridine preceding the cleavage site 
[18]. In addition, base pairing must be maintained 
between the end of the 5’ exon and the 5’ exon- 
binding site present in the ribozyme so that the 
ribozyme can hold onto the 5’ exon after cleavage. 
These base pairs can be composed of almost any sets of 
complementary nucleotides, however [18]. 
Ribozyme-mediated trans-splicing 
In addition to performing a self-splicing‘ reaction, a 
slightly shortened version of the group I ribozyme from 
Tetrukymena can trans-splice an exon attached to its 3’ end 
onto a targeted 5’ exon RNA which is a separate RNA 
molecule [l&-20] (Fig. 2b). In this reaction, the 5’ exon is 
recognized by the group I ribozyme via base pairing 
through its 5 exon-binding site. In the process of pairing, 
a uridine is positioned across from the guanosine present 
at the 5’ end of the 5’ exon-binding site of the ribozyme. 
Once positioned, the ribozyme catalyzes the cleavage of 
the substrate RNA at the reconstructed 5’ splice site and 
then ligates its 3’ exon onto the 5’ exon cleavage product. 
Trans-splicing by group I ribozymes is extremely mal- 
leable because there are very few sequence requirements 
Fig. 3. Scheme to correct mutant trans- 
cripts with targeted trans-splicing. 
Mutant messages can be recognized by 
a ribozyme at any uridine (red) 
upstream of the mutation (marked by 
Xm). The ribozyme then removes the 
sequence containing the mutation (light 
blue) and replaces it with a 3’ exon that 
encodes the correct sequence for 
the wild-type transcript (XWt; correct 
sequence shown in yellow). 
for the exons in this reaction. Virtually any uridine 
residue in a 5’ exon can be targeted for splicing; it is only 
necessary to alter the nucleotide composition of the 5’ 
exon-binding site to make it complementary to the 
target site. Because no specific 3’ exon sequences are 
required, trans-splicing ribozymes of this kind could be 
designed that would be able to splice virtually any 3’ 
exon sequence onto a targeted 5’ exon. 
Trans-splicing ribozymes can indeed be used to revise the 
RNA revision by trans-splicing 
sequence of targeted RNAs. In the first example of this 
application, the group I ribozyme from Tetrukymem was 
re-engineered to repair truncated lucZ transcripts via tar- 
geted trans-splicing [20]. In this system, the ribozyme’s 
normal 3’ exon was replaced with 200 nucleotides of lacZ. 
For trans-splicing to correct the defective lacZ messages, 
the ribozyme must recognize the truncated 5’ 1acZ RNA 
by base pairing, cleave off additional nucleotides, hold 
onto the 5’ exon cleavage product by maintaining base 
pairing through the 5’ exon-binding site of the ribozyme 
and ligate the EucZ 3’ exon sequence onto the cleaved 5’ 
product to yield the correct translational reading frame. It 
was shown that the ribozyme could faithfully accomplish 
such RNA revision both in vitro and in Esckerickia coli. 
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Furthermore, in E. coli the repaired RNAs went on to be 
translated to produce the correct protein product, the (Y- 
complement of B-galactosidase [20]. A generalization of 
this strategy is shown in Figure 3. 
In this example, the properties of a group I RNA enzyme 
were exploited to revise mutant RNA messages in transit 
along the E. coli information superhighway. If similar revi- 
sions are possible in mammalian cells, these splicing 
ribozymes may represent very useful therapeutic agents. 
Altering genetic instructions at the RNA level for thera- 
peutic ends is appealing intellectually because, as noted 
above, the information in most genetic messages is revised 
normally by similar cellular processes before translation. 
Therapeutic applications of RNA revision 
In this era of molecular medicine, the genetic basis of an 
increasing number of inherited diseases is being discov- 
ered. Gene therapy represents a new and exciting 
approach to the treatment of such diseases [21,22]. 
Conceptually, gene therapy is quite simple. To treat a 
genetic deficiency, one would introduce a functional 
version of the defective gene into the cells of the de& 
cient patient.To accomplish this in practice, most often a 
viral vector is used to transfer a cDNA copy of the wild- 
type gene, usually under the control of a heterologous 
promoter, to cells harboring a mutant version of the 
gene. If the human genome were a simple warehouse of 
information, this approach would probably be quite suc- 
cessful. Unfortunately for the gene therapist, our genome 
appears to be extremely complicated, and expression of 
the information contained within it appears to be highly 
regulated. This complexity may severely limit the utility 
of the simple ‘add-back’ approach to gene therapy. 
cDNA versions of genes that are integrated in incorrect 
locations in the genome and that are expressed from het- 
erologous promoters will almost certainly not recapitu- 
late the normal expression pattern of the endogenous 
gene. Therefore, unless significant technical advances are 
made, the add-back approach may only be useful for the 
treatment of genetic disorders associated with genes that 
do not require regulated expression to function properly 
RNA revision may offer a solution to this problem. 
Using trans-splicing ribozymes to alter RNA messages, 
defective transcripts can be emended to encode a wild- 
type version of a gene product (Fig. 3). This approach 
will mainly be useful for conditions resulting from a 
defective gene that contains a point mutation or deletion 
that does not alter the expression pattern of the gene; 
such defects occur in many genetic diseases, including 
sickle-cell anemia and cystic fibrosis. Trans-splicing in 
mutant cells of this kind should yield a corrected gene 
product only at the proper times, because repair can only 
occur when the targeted, mutant transcript is present. 
RNA repair may be especially appropriate for the treat- 
ment of genetic disorders characterized by gene defects 
that result in the production of deleterious or dominant- 
mutant proteins, such as sickle-cell anemia and certain 
cancers. Ideally, genetic treatment of these maladies 
should inhibit the production of the mutant protein and 
engender the production of the wild-type product. By 
repairing mutant messages, trans-splicing ribozymes 
might be able to accomplish both tasks simultaneously. 
RNA revision via trans-splicing or other means is thus a 
new and potentially very useful alternative approach to 
genetic therapy for inherited diseases. 
The significant hurdles ahead 
The hypothesis that RNA revision can be useful in the 
clinic for the treatment of genetic deficiencies remains 
largely untested. Enzymologists have studied the in vitro 
trans-splicing reaction catalyzed by the group I intron 
for several years [15,16,18,19].The scientific foundation 
laid by these studies has recently allowed biologists to 
begin to employ similar reactions to repair. mutant 
RNAs in bacteria [20]. Now we must begin to deter- 
mine if targeted trans-splicing can proceed in mam- 
malian cells as well. Once in viva experimental systems 
are available, biologists, enzymologists and chemists will 
have to work together to address the many unanswered 
questions about trans-splicing reactions in the mam- 
malian cellular milieu. What limits the rate of ribozyme- 
mediated RNA repair inside eukaryotic cells? If 
necessary, can the overall reaction rate and efficiency be 
increased? Does the ribozyme react only with its tar- 
geted substrate in viva or does it react with a large 
number of incorrect RNAs? If necessary, can specificity 
be increased? How does RNA trafficking and metab- 
olism influence such reactions? These questions need to 
be answered before we can accurately assess how useful 
group-I-mediated RNA revision is likely to be. Even if 
a useful trans-splicing ribozyme can be made, improve- 
ments in gene transfer and expression systems will 
almost certainly be required to give stable expression of 
ribozymes inside cells, so that they can repair the mutant 
RNAs for extended periods of time. Nevertheless, the 
concept of directed RNA revision is intriguing and 
deserves attention. Other RNA revision strategies that 
employ different ribozymes, protein enzymes, or RNPs 
to modify RNA messages in a variety of ways should be 
explored, and the utility of RNA repair by trans-splicing 
ribozymes should be assessed. 
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